Navigation Links
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
Date:5/15/2008

f hospitalization and mortality and affects about 2.5 million people in the United States, as well as 4.5 million people in the European Union and is emerging as a growing public health concern because of the aging of the population. Patients suffering from atrial fibrillation have twice the risk of death, an increased risk of stroke and cardiovascular complications, including congestive heart failure. Furthermore atrial fibrillation considerably impairs patients' lives, mainly because of their inability to perform normal daily activities due to complaints of palpitations, chest pain, dyspnoea, fatigue or light-headedness, without consideration of the cumbersome and sometime serious constraints imposed by current therapies of atrial fibrillation.

"In atrial fibrillation where treatment morbidity-mortality benefit still needed to be demonstrated, ATHENA is a unique trial using clinically relevant outcomes such as cardiovascular hospitalization or death as the primary endpoint. In this regard, the trial has clearly achieved these safety and efficacy endpoints," said Dr Stefan H. Hohnloser, J.W. from the Goethe University, Division of Clinical Electrophysiology, Frankfurt, Germany, who served as co-principal investigator of the ATHENA study. "As a consequence, dronedarone is the first potential treatment for atrial fibrillation, which was demonstrated in the ATHENA trial to reduce cardiovascular hospitalization or mortality in patients with AF," he added.

The most frequently reported adverse events of Multaq(R) vs. placebo induced gastro-intestinal effect (26% vs. 22%), skin disorder (10% vs. 8%, mainly rash) and increased blood creatinine (4.7% vs. 1%). The mechanism of blood creatinine increase (inhibition of creatinine secretion at the renal tubular level) was well defined, in a separate study of healthy volunteers. Multaq(R) showed a rate of pro-arrhythmia similar to placebo and no excess of hospitalizations for congestive heart failure. There was a s
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
2. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
3. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
4. Hospital Launches Landmark Emergency Medicine Project
5. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
6. Viatronix V3D-Colon Utilized in Another Landmark Study
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
11. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... SAN FRANCISCO, Calif. , Aug. 28, 2015 /PRNewswire/ ... for the treatment of cancer, today announced the filing ... U.S. Securities and Exchange Commission (SEC) relating to a ... number of shares to be offered and the price ... CytomX intends to list its common stock under the ...
(Date:8/28/2015)... Research and Markets ... the "12th Annual Report and Survey of ... their offering. The 2015 12th Annual ... Production is the most recent study of biotherapeutic ... future capacity and production. The report contains the ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by AstraZeneca plc, quetiapine ... important drug for the treatment of schizophrenia. Approved ... was listed in the Catalogue of Drugs for ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Quetiapine Market Investigation Report 2010-2019 2
... Dec. 19, 2011  Levi & Korsinsky is investigating potential ... or the "Company") (NYSE: IVC ) securities ... For more information, click here: http://zlk.9nl.com/invacare-ivc/ . ... plunged over 25% on heavy volume after the Company ...
... 2011  Qforma, the leading provider of healthcare analytics and ... the appointment of Ian McGuinness to the position of ... pleased to welcome Ian to our team as we ... of the pharmaceutical business," said Al Reicheg, Chief Commercial ...
Cached Medicine Technology:The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Securities Laws Violations by Invacare Corporation 2Qforma Appoints Ian McGuinness as Vice President, Business Development 2
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business ... veterans leading in business. Mr. Troy Mizell, Chairman of the Board at ... Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, through their ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout Southern ... sea diving. The act of recreational diving exposes the body to extreme ... is vital that all recreational and professional divers undergo regular comprehensive scuba physicals. ...
(Date:8/28/2015)... ... August 28, 2015 , ... United Benefit Advisors ... TJS Insurance Group as its newest Partner Firm. Founded in 1924 and headquartered ... them focused on their goals. Within the past 10 years, TJS Insurance Group ...
(Date:8/28/2015)... Abilene, Texas (PRWEB) , ... August 28, 2015 , ... ... penned a new publication and pleads for swift actions to be taken in ... of unnatural disasters. , Yisrayl says scientists have yet to understand fully the ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Healthpointe Now Offering Scuba Physicals 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2
... PICK: Connexins: providing protection to cells destroyed in type ... lifelong disease characterized by high levels of sugar (glucose) ... immune system attacking and destroying the cells in their ... glucose levels. Surprisingly, little is known about the mechanisms ...
... Goodwin HealthDay Reporter , SUNDAY, Nov. 6 ... fresheners may evoke the holiday season for some. For ... runny, itchy noses and sneezing to asthma attacks. ... risen, so have complaints from their patients about reactions ...
... for the first time, they show significant decreases in crime, ... Researchers assessed more than 200 at-risk boys annually from ... crime, tobacco, alcohol, and marijuana use changed over time. While ... behavior, they had not isolated the additional effects of fatherhood. ...
... cells know what cell types to become? Why do cells ... develop into cancer cells? These are some of the questions ... research has a very strong position internationally and one of ... of Copenhagen. She has just received an ERC Starting Grant ...
... School of Medicine is honored to announce gifts to ... Research Foundation Professorship in Integrative Oncology. This professorship will ... as national leaders in teaching, research, and patient care ... gifts from The Parker Foundation and Helen Moss Cancer ...
... published research shows that more patients with end-stage ... hemodialysis as their initial kidney replacement therapy over ... the study now available in Arthritis Care ... College of Rheumatology (ACR), also found that African ...
Cached Medicine News:Health News:JCI online early table of contents: Nov. 7, 2011 2Health News:JCI online early table of contents: Nov. 7, 2011 3Health News:JCI online early table of contents: Nov. 7, 2011 4Health News:JCI online early table of contents: Nov. 7, 2011 5Health News:JCI online early table of contents: Nov. 7, 2011 6Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 2Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 3Health News:Fatherhood can help change a man's bad habits 2Health News:Research in cellular memory 2Health News:Pioneering professorship will teach innovative, patient-centered approach to cancer 2Health News:Pioneering professorship will teach innovative, patient-centered approach to cancer 3Health News:Most lupus nephritis patients with end-stage renal disease opt for hemodialysis therapy 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: